Published in Pharm Res on February 24, 2017
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med (2009) 21.74
Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nat Genet (2003) 16.51
CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clin Pharmacol Ther (2011) 10.95
Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst (2009) 7.95
The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group. Genet Med (2009) 5.69
Drug-related morbidity and mortality: updating the cost-of-illness model. J Am Pharm Assoc (Wash) (2001) 4.88
Barriers to the provision of genetic services by primary care physicians: a systematic review of the literature. Genet Med (2003) 3.55
Adoption of pharmacogenomic testing by US physicians: results of a nationwide survey. Clin Pharmacol Ther (2012) 3.22
What is the clinical utility of genetic testing? Genet Med (2006) 3.01
On the synthesis and interpretation of consistent but weak gene-disease associations in the era of genome-wide association studies. Int J Epidemiol (2006) 2.66
Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA (2001) 2.49
Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials. Ann Oncol (2014) 2.31
Meta-analysis: Its strengths and limitations. Cleve Clin J Med (2008) 2.15
Evaluating the utility of personal genomic information. Genet Med (2009) 2.08
Addressing the challenges of the clinical application of pharmacogenetic testing. Clin Pharmacol Ther (2009) 1.99
Pharmacogenomics: challenges and opportunities. Ann Intern Med (2006) 1.96
Recommendations from the EGAPP Working Group: can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? Genet Med (2009) 1.94
Development and implementation of a pharmacist-managed clinical pharmacogenetics service. Am J Health Syst Pharm (2011) 1.85
Pharmacogenomics in the clinic. Nature (2015) 1.71
Emergence and evolution of pharmacogenetics and pharmacogenomics in clinical pharmacy over the past 40 years. Ann Pharmacother (2007) 1.62
Assessment of the pharmacogenomics educational needs of pharmacists. Am J Pharm Educ (2011) 1.62
Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review. Genet Med (2009) 1.49
Personalized medicine and genomics: challenges and opportunities in assessing effectiveness, cost-effectiveness, and future research priorities. Med Decis Making (2010) 1.45
A network of investigator networks in human genome epidemiology. Am J Epidemiol (2005) 1.43
Introduction to genetic association studies. Cold Spring Harb Protoc (2012) 1.38
Improving the efficiency and relevance of evidence-based recommendations in the era of whole-genome sequencing: an EGAPP methods update. Genet Med (2012) 1.34
From pharmacogenetics to personalized medicine: a vital need for educating health professionals and the community. Pharmacogenomics (2004) 1.31
Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation. J Natl Cancer Inst (2010) 1.30
Outcomes of interest in evidence-based evaluations of genetic tests. Genet Med (2010) 1.30
General practitioners' and pharmacists' perceptions of the role of community pharmacists in delivering clinical services. Res Social Adm Pharm (2009) 1.28
Pharmacogenomics: from bedside to clinical practice. Hum Mol Genet (2006) 1.28
Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer. Br J Cancer (2015) 1.28
What is clinical utility and why should we care? Clin Pharmacol Ther (2010) 1.27
Pharmacogenetics, the next challenge for pharmacy? Pharm World Sci (2006) 1.26
A personalized approach to cancer treatment: how biomarkers can help. Clin Chem (2008) 1.25
Germline pharmacogenomics in oncology: decoding the patient for targeting therapy. Mol Oncol (2012) 1.20
Assessing the clinical utility of diagnostics used in drug therapy. Clin Pharmacol Ther (2010) 1.16
The current clinical practice of pharmacogenetic testing in Europe: TPMT and HER2 as case studies. Pharmacogenomics J (2006) 1.14
Abacavir hypersensitivity: a model system for pharmacogenetic test adoption. Genet Med (2008) 1.14
The EGAPP initiative: lessons learned. Genet Med (2013) 1.11
Criteria influencing the clinical uptake of pharmacogenomic strategies. BMJ (2004) 1.08
The human genome project is complete. How do we develop a handle for the pump? Am J Epidemiol (2003) 1.07
A multi-dimensional model of clinical utility. Int J Qual Health Care (2006) 1.01
Use of molecular markers for predicting therapy response in cancer patients. Cancer Treat Rev (2010) 1.01
Scientific challenges and implementation barriers to translation of pharmacogenomics in clinical practice. ISRN Pharmacol (2013) 0.98
Pharmacogenetics approach to therapeutics. Clin Exp Pharmacol Physiol (2006) 0.98
Pharmacogenetic testing: time for clinical practice guidelines. Clin Pharmacol Ther (2011) 0.98
Putting pharmacogenetics into practice. Nat Biotechnol (2006) 0.97
The Coriell personalized medicine collaborative pharmacogenomics appraisal, evidence scoring and interpretation system. Genome Med (2013) 0.95
Pharmacogenetics: from discovery to patient care. Am J Health Syst Pharm (2009) 0.93
Integrating pharmacogenetics into society: in search of a model. Nat Rev Genet (2004) 0.93
Genomic epidemiology of complex disease: the need for an electronic evidence-based approach to research synthesis. Am J Epidemiol (2005) 0.90
Evidence required to demonstrate clinical utility of pharmacogenetic testing: the debate continues. Clin Pharmacol Ther (2014) 0.90
Clinical delivery of pharmacogenetic testing services: a proposed partnership between genetic counselors and pharmacists. Pharmacogenomics (2013) 0.89
The clinical utility of precision medicine: properly assessing the value of emerging diagnostic tests. Clin Pharmacol Ther (2010) 0.86
Pharmacogenetics: data, concepts and tools to improve drug discovery and drug treatment. Eur J Clin Pharmacol (2008) 0.86
Useless until proven effective: the clinical utility of preemptive pharmacogenetic testing. Clin Pharmacol Ther (2014) 0.85
A public health approach to pharmacogenomics and gene-based diagnostic tests. Pharmacogenomics (2006) 0.83
Exploration of the perceptions, barriers and drivers of pharmacogenomics practice among hospital pharmacists in Adelaide, South Australia. Pharmacogenomics J (2013) 0.83
Personalized medicine: potential, barriers and contemporary issues. Curr Drug Metab (2012) 0.82
What will it take to reap the clinical benefits of pharmacogenomics? Food Drug Law J (2006) 0.81
The role of meta-analysis in cancer clinical trials. Int J Clin Oncol (2009) 0.80
Cost-effectiveness of genotyping to guide treatment. Pharmacogenomics (2014) 0.80
Challenges and limitations in the interpretation of systematic reviews: making sense of clopidogrel and CYP2C19 pharmacogenetics. Clin Pharmacol Ther (2013) 0.80
Pharmacogenomic and pharmacogenetic-guided therapy as a tool in precision medicine: current state and factors impacting acceptance by stakeholders. Genet Res (Camb) (2015) 0.79
Genetic association studies of cancer: where do we go from here? Cancer Epidemiol Biomarkers Prev (2007) 0.78
Meta-analysis comparing the efficacy of anti-EGFR monoclonal antibody therapy between KRAS G13D and other KRAS mutant metastatic colorectal cancer tumours. Eur J Cancer (2016) 0.78
Translation of pharmacogenetic knowledge into cancer therapeutics. Clin Adv Hematol Oncol (2007) 0.78
Developing pharmacogenetic evidence throughout clinical development. Clin Pharmacol Ther (2010) 0.77
Establishing clinical utility of pharmacogenetic tests in the post-FDAAA era. Clin Pharmacol Ther (2010) 0.77
Pharmacists and pharmacogenetics. Am J Health Syst Pharm (2009) 0.77
Clinical significance of prognostic and predictive markers in colorectal cancer. Pharmacogenomics J (2002) 0.77
The perceptions of pharmacists in Victoria, Australia on pharmacogenetics and its implications. Pharm Pract (Granada) (2011) 0.76
Interpreting the clinical utility of a pharmacogenomic marker based on observational association studies. Pharmacogenomics J (2013) 0.76
Evolving research and stakeholder perspectives on pharmacogenomics. JAMA (2011) 0.76
Pharmacogenomics in Primary Care: A Crucial Entry Point for Global Personalized Medicine? Curr Pharmacogenomics Person Med (2012) 0.76
Pharmacogenomic substudies of randomized controlled trials: consideration of safety outcomes. Ther Adv Drug Saf (2014) 0.76
Pharmacists in Australian general practice: an opportunity for expertise in precision medicine. Ther Adv Drug Saf (2015) 0.75
Pharmacogenomic substudies of randomized controlled trials: consideration of safety outcomes. Ther Adv Drug Saf (2014) 0.76
Pharmacists in Australian general practice: an opportunity for expertise in precision medicine. Ther Adv Drug Saf (2015) 0.75
Prediction of olanzapine exposure in individual patients using physiologically-based pharmacokinetic modelling and simulation. Br J Clin Pharmacol (2017) 0.75